• Explore /
  • Poster
  • / BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors.

BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors.

Abstract Poster

Authors

null

Yufei Liu

Jiangsu Cancer Hospital, Nanjing, China

Yufei Liu , Zhisong He , Mingjun Zhang , Shusuan Jiang , Dahong Zhang , Miao Feng , Shenhong Qu , Wutong Ju , Ke Wang , Ramil Abdrashitov , Jifeng Feng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

NCT05014828

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 2610)

DOI

10.1200/JCO.2024.42.16_suppl.2610

Abstract #

2610

Poster Bd #

89

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Mehmet Akce

Poster

2022 ASCO Annual Meeting

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.

First Author: Sujana Movva

First Author: Vicky Makker